Skip to main content

miReculeRESIAt RESI Boston 2024, held on September 25th at the Westin Copley Place, Montgomery County-based biotechnology company miRecule, a client of BioHealth Innovation Inc. (BHI), showcased its groundbreaking RNA therapeutic programs. As part of Biotech Week Boston, RESI Boston provided a premier opportunity for miRecule to engage in in-person networking with potential investors and partners, followed by virtual partnering sessions on September 26-27. miRecule presented the innovative work stemming from its DREAmiR™ platform, which leverages genomic and patient outcome data to create highly personalized RNA therapies for cancer and muscular dystrophy.

miRecule highlighted its lead programs in Head & Neck Cancer and Facioscapulohumeral Muscular Dystrophy at the event. Their DREAmiR™ platform, designed to target specific genetic abnormalities underlying these diseases, positions miRecule as a leader in precision medicine. The company’s ability to tailor RNA therapies based on patient data offers promising advancements for patients struggling with debilitating conditions, aiming to create a future where they can live free from the burden of their disorders.

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.